<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100808">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889459</url>
  </required_header>
  <id_info>
    <org_study_id>J-CTOPCI-ER2013</org_study_id>
    <nct_id>NCT01889459</nct_id>
  </id_info>
  <brief_title>Japanese CTO PCI Expert Registry</brief_title>
  <official_title>Patient Registry of Percutaneous Coronary Intervention (PCI) for Chronic Total Occlusion (CTO) by Japanese Experts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kurashiki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japanese CTO PCI Expert Registry investigators</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kurashiki Central Hospital</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a consensus of treatment strategy of percutaneous
      coronary intervention (PCI) for chronic total occlusion (CTO) through patient registry of
      PCI for CTO performed by Japanese certified operators.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>successful revascularization without any major adverse cardiocerebral events (MACCE) at early follow-up and MACCE during the 5-year follow-up</measure>
    <time_frame>within the first 1 month (plus 1 month) after PCI and during the 5-year follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>early and late results on major adverse cardiocerebral events (MACCE): all-cause death, coronary artery bypass grafting, re-PCI (target lesion revascularization/target vessel revascularization), admission for heart failure, myocardial infarction, admission for unstable angina, cerebrovascular disease, stent thrombosis in 19000 patients in and outside Japan</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">19000</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>PCI for CTO</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent PCI for CTO lesions by Japanese certified operators
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients eligible for PCI

        Patients who underwent PCI for CTO lesions that contain the following:

          1. Thrombolysis in myocardial infarction trial (TIMI) 0

          2. The occlusive period more than 3 months or unknown

          3. The main coronary arteries (segment 1-3, 5-8, 11, 13), branches that have large
             perfusion area (segment 4PL, 9/10, 12) and graft

        Exclusion Criteria:

        Patients ineligible for PCI judged in clinical practice
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keiko Oka</last_name>
    <phone>81-86-422-0210</phone>
    <phone_ext>2742</phone_ext>
    <email>cto.e.registry@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harumi Katoh, MD, PhD</last_name>
    <phone>81-86-422-0210</phone>
    <email>hk10731@kchnet.or.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiko Oka</last_name>
      <phone>81-86-422-0210</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 1, 2013</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
